7月31日，赛诺菲公布2025H1业绩，上半年总营收198.89亿欧元（约218.00亿美元，按2025年平均汇率换算，1欧元=1.0961美元，下同），同比增长9.9%（按固定汇率计算，下同）；研发投入37.17亿欧元（约40.74亿美元），占总营 ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclinical and phase 1 vaccine candidates to expand its respiratory syncytial virus (RSV) pipeline beyond mRNA.

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season. Paris, June 9, 2025. Sanofi is shipping Beyfortus starting in early Q3 to ...

Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which typically starts in November ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline. Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd, a privately held ...

FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 3:15 pm ...

Nitya Padmanabhan, head of Sanofi Vaccines (India) said, “Bringing Beyfortus to India is a pivotal step in our mission to protect every child from immunisation preventable diseases like RSV.

RSV is the leading cause of hospitalization in infants up to 1 year old. Most babies with RSV need extra oxygen; doctors help support their breathing for two or three days, and then they get better.